There is a steady increase in the number and scope of strategic alliances between biotechnology and pharmaceutical companies [2], because in an increasingly cost-conscious environment pharmaceutical companies need innovative products to achieve premium pricing and gain market share. Biotechnology companies continue to invest heavily in research and development and, by this, serve as a source of products, technologies and know-how for pharmaceutical companies. Besides M&A (Mergers and acquisitions), strategic alliances are considered as a very important and widespread possibility in order to gain access to the knowledge incorporated in biotechnology companies [1,3]. Powell et al. [4] points out that the core capabilities of organizations are derived from knowledge-seeking and knowledge creation.
展开▼
